EraCal Therapeutics: Novartis Venture Fund and UZH Foundation invest CHF1M in an anti-obesity drug
EraCal Therapeutics, developing the first-in-class anti-obesity drug, has secured its first investment from Life Sciences Fund. The capital will enable EraCal to kick-off its lead optimization program.
Read full article »
EraCal Therapeutics is a biotechnology company that develops and commercializes drugs to treat anti-obesity problems.
Read more